IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 05/06/2020 - Press release

    Dr. Clara Montagut, awarded a I CRIS Programme of Excellence in Cancer Research

    Detecting the best research talents and providing these people with financial, structural and stability means advancing in cancer care via translational research projects that improve treatment and diagnosis through innovation with clinical application. This is the ambitious goal of the innovative and cutting-edge I CRIS Research Programmes promoted by CRIS against cancer, which have already received their first awards thanks to a meticulous evaluation and selection process led by a prestigious committee of international experts. Over the next five years, the three winning projects will focus on colorectal cancer (the second-ranked cancer in terms of deaths) prostate cancer (diagnosed in 1.3 million people each year), and immunotherapy, a highly innovative type of treatment that is changing the outlook of many cancers. "Research is our life and only through research are we going to find a cure for cancer. With the CRIS Research Programmes we want to detect the best research talent and provide these people with financial and work-related peace of mind. We want to discover and support the Nobel Prize winners of tomorrow and these first CRIS Programmes are just the beginning. In the next edition we will double the number of winners, underlining our commitment to research in spite of the current situation we are experiencing",explains Diego Megía, president of CRIS against cancer.

    Més informació "Dr. Clara Montagut, awarded a I CRIS Programme of Excellence in Cancer Research"

  • 28/05/2020 - Press release

    New resource to assist SMEs in managing the effects of COVID-19 on the mental health and well-being of their workers

    The impacts of the COVID-19 pandemic are far reaching and long lasting for people working in Small and Medium Enterprises (SMEs) in terms of people's wellbeing and mental health and the social and economic impacts. he EU-funded large-scale MINDUP project ("Mental Health Promotion and Intervention in Occupational Settings") began in January 2020. MINDUP aims to improve mental health and wellbeing in the workplace by developing, implementing and evaluating a multilevel intervention targeting both prevalent psychiatric disorders (depression, anxiety disorders) and non-clinical aspects of mental health (stress, burnout, wellbeing, depressive symptoms).

    Més informació "New resource to assist SMEs in managing the effects of COVID-19 on the mental health and well-being of their workers"

  • 25/05/2020 - Press release

    Alliance between the Hospital del Mar Medical Research Institute and Chemotargets to accelerate the design of new cancer therapies

    The company Chemotargets -based in the Barcelona Science Park and a global leader in the development of computational platforms for the design, optimization and safety evaluation of drugs- has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) in order to accelerate research projects for the discovery and development of new oncological therapies that respond to important unmet medical needs. This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between the IMIM experience in the identification of new therapeutic targets in emerging fields of cancer biology and the Chemotargets expertise in drug discovery and development. This initiative will include the use of cutting-edge computational technologies developed specifically to rapidly design drug candidates acting on new mechanisms of action or directed to targets that are difficult to address and for which no identified drugs currently exist.

    Més informació "Alliance between the Hospital del Mar Medical Research Institute and Chemotargets to accelerate the design of new cancer therapies"

  • 06/05/2020 - Press release

    The FDA licenses Chemotargets CLARITY platform

    The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest. This contract is meant to directly address the FDA's requirement for a computational method which can predict potential molecular targets from chemical structure and provide a user-friendly environment for analysis of results. Molecular targets identified with high confidence by CLARITY® may be evaluated by FDA/CDER for their association with adverse events, addiction liability, or their association with disease within the specified indication(s).

    Més informació "The FDA licenses Chemotargets CLARITY platform"

  • 04/05/2020 - Press release

    New therapeutic targets for treating memory impairment in Down syndrome

    A team of researchers led by Dr. Victoria Puig from the Hospital del Mar Medical Research Institute (IMIM), which also involved the Centre for Genomic Regulation (CRG), has studied the neural basis of intellectual disability in mice with Down syndrome and has discovered that the neural networks of brain circuits relevant to memory and learning are over-activated and that the connectivity of these circuits is poor. The researchers have also observed that neural activity during sleep is abnormal and probably interferes with memory consolidation. The study has even identified biomarkers in brain rhythms that can predict memory deficits in the mice which are corrected by chronic treatment with a natural component of green tea, epigallocatechin gallate, which other studies have already shown to improve executive function in adults with Down syndrome.

    Més informació "New therapeutic targets for treating memory impairment in Down syndrome"

  • 24/04/2020 - Press release

    Biomolecules from olive oil may have beneficial effects on blood vessel health

    Up to now, it was not known what happened in the human body after maslinic acid and oleanolic acid were consumed in diet-compatible quantities, in other words, what happened from the moment they were ingested until their total elimination from the body, what is referred to as pharmacokinetics. Furthermore, information on the biological activity of these biomolecules in the human body is very scarce in the scientific literature.  Using a method for determining oleanolic and maslinic acids in plasma developed by the Integrated Pharmacology and Systems Neuroscience Research Group at the Hospital del Mar Medical Research Institute (IMIM), and the Barcelona Mar Health Park Consortium node of the Physiopathology of Obesity and Nutrition (CIBERobn) network, as part of the NUTRAOLEUM research project, a clinical trial on humans has evaluated the pharmacokinetics of these two triterpenic acids from the olive tree after the ingestion of olive oils enriched in these biomolecules at two different concentrations. In addition, the effect of these triterpenic acids on endothelial function has also been studied, revealing that they contribute to preserving blood vessel health and preventing arteriosclerosis.

    Més informació "Biomolecules from olive oil may have beneficial effects on blood vessel health"

  • 17/04/2020 - Press release

    Chemotargets opens an investment round to enter a new phase of growth

    Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to become a biotechnology company that will develop new medicines in multiple therapeutic areas, with an initial focus on oncology. Founded in 2006 as a spin-off from Dr. Jordi Mestres' Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute, a leading academic centre of excellence based in Barcelona, Chemotargets is opening an investment round to undertake the transformation of its business model. Genesis Biomed, a well-established consultancy firm in the health and biotech sectors, and CREA Inversión, an M&A boutique advisory firm specialised in corporate transactions and financing, will advise Chemotargets in this transformation.

    Més informació "Chemotargets opens an investment round to enter a new phase of growth"

  • 12/03/2020 - Press release

    Key piece in generating blood stem cells in the laboratory discovered

    Researchers from the Stem Cell and Cancer Group at the Hospital del Mar Institute for Medical Research (IMIM) have led a study in which they have been able to determine the role of two molecules, Dll4 and Notch, and the importance of their relationship in the generation of blood stem cells. This is a very important step in the search to find a viable method for generating ­­this type of cell in the laboratory. The study, which included researchers from the universities of Tel Aviv, Edinburgh, the Sorbonne in Paris, and Cambridge, has been published in The EMBO Journal. The group that led the study is one of the few Spanish teams working in this field, and for years they have been making breakthroughs in their research into blood stem cells and generating these in the laboratory, in the field of regenerative medicine. Right now, "We can make erythrocytes, platelets, a lot of blood products in the lab, but we have never been able to make a cell that has the characteristics of blood stem cells", explains Dr. Anna Bigas, coordinator of the group and first author of the study. Being able to find a method for generating this type of cell in the laboratory would allow patients with diseases like leukaemia, or certain genetic pathologies that affect the blood, and who do not have a compatible donor, to receive a haematopoietic stem cell transplant. In many cases this is the only treatment possible.

    Més informació "Key piece in generating blood stem cells in the laboratory discovered"

  • 06/02/2020 - Press release

    The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases

    Ten years ago, researchers at Hospital del Mar Medical Research Institute (IMIM) and at Pompeu Fabra University (UPF) created a computer platform for collecting highly relevant scientific information that had, until then, been scattered across several sources: relationships between genes and diseases. This open access tool called DisGeNET has become a benchmark in the field of research. From now on, it will also have an industrial application thanks to MedBioinformatics Solutions, a spin-off of IMIM and UPF that is to develop software and consulting services that will bring added value to the information of DisGeNET to help companies develop new products and services. The company came to life today, 6 February, with the signing of the deeds of incorporation by the acting director of IMIM, Jorge Martínez, the UPF general manager, Jaume Badia; the researchers and partners of the company, Ferran Sanz, Laura Furlong, Janet Piñero and Olga Valverde, and the investor partners: Frederic Abelló and the companies Prous Institute for Biomedical Research and Icrowd+D.

    Més informació "The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases"

  • 16/12/2019 - Press release

    Hospital costs estimated of occupational diseases not recognized by the Social Security

    A new study has estimated the exact, individualized cost of healthcare for patients being treated in hospital for an occupational disease not recognized by the Social Security. The study was conducted by researchers from the Center for Research in Occupational Health (CiSAL) at Pompeu Fabra University (UPF), the Hospital del Mar Medical Research Institute (IMIM) and the Occupational Health Service at Hospital del Mar  As in other countries, Spain has two public health systems. On the one hand, the National Health Service, financed by taxes, covering all residents. On the other hand, the Social Security System is specific for occupational diseases, administered primarily by the mutual insurance companies that collaborate with the Social Security system, funded by contributions by employees and employers, which only offers protection to employees affiliated to the Social Security system.

    Més informació "Hospital costs estimated of occupational diseases not recognized by the Social Security"

Contact

Head of Communications:
Rosa Manaut(ELIMINAR)

Communications office:
Marta Calsina(ELIMINAR)

Tel:
(+34) 93 316 06 80
(+34) 699 094 833

Doctor Aiguader, 88
08003 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact